MEMBER'S LOGINX
| Login Failure | ||||||||
|
||||||||
| Sign Up | Forgot Password? | ||||||||
- Home
- Research It
- Compare Company
- International - indian pharma
- CADILA HEALTHCARE - ADCOCK INGRAM (S. Africa)
CADILA HEALTHCARE vs ADCOCK INGRAM (S. Africa) - Comparison Results
CADILA HEALTHCARE Change
Cadila Healthcare is one of the leading players in the Indian pharma market having a presence in both the domestic and international markets. In the international markets, the company had adopted the strategy of competing directly in the generics mar... More
ADCOCK INGRAM (S. Africa)
Adcock Ingram is a leading South African pharmaceutical manufacturer, marketer and distributor. The company occupies 10% share of the private pharmaceutical market in South Africa with a strong presence in over-the-counter (OTC) brands. Adcock is als... More
Financials
 CADILA HEALTHCARE  ADCOCK INGRAM |
| EQUITY SHARE DATA | |||||
|---|---|---|---|---|---|
| CADILA HEALTHCARE Mar-20 |
ADCOCK INGRAM Jun-14 |
CADILA HEALTHCARE/ ADCOCK INGRAM |
5-Yr Chart Click to enlarge
|
||
| High | Rs | 352 | 360 | - | |
| Low | Rs | 207 | 260 | - | |
| Sales per share (Unadj.) | Rs | 139.2 | 107.2 | - | |
| Earnings per share (Unadj.) | Rs | 11.8 | -27.0 | - | |
| Cash flow per share (Unadj.) | Rs | 18.6 | -22.4 | - | |
| Dividends per share (Unadj.) | Rs | 3.50 | 0 | - | |
| Dividend yield (eoy) | % | 1.3 | 0 | - | |
| Book value per share (Unadj.) | Rs | 101.4 | 84.1 | - | |
| Shares outstanding (eoy) | m | 1,023.74 | 168.78 | - | |
| Bonus/Rights/Conversions | - | - | - | ||
| Price / Sales ratio | x | 2.0 | 2.9 | 69.4% | |
| Avg P/E ratio | x | 23.7 | -11.5 | -206.8% | |
| P/CF ratio (eoy) | x | 15.0 | -13.9 | -108.6% | |
| Price / Book Value ratio | x | 2.8 | 3.7 | 74.8% | |
| Dividend payout | % | 29.8 | 0 | - | |
| Avg Mkt Cap | Rs m | 286,033 | 52,343 | 546.5% | |
| No. of employees | `000 | 13.4 | 4.3 | 312.3% | |
| Total wages/salary | Rs m | 24,145 | 3,285 | 735.0% | |
| Avg. sales/employee | Rs Th | 10,632.7 | 4,214.0 | 252.3% | |
| Avg. wages/employee | Rs Th | 1,801.2 | 765.2 | 235.4% | |
| Avg. net profit/employee | Rs Th | 898.5 | -1,061.8 | -84.6% | |
| INCOME DATA | |||||
|---|---|---|---|---|---|
| Net Sales | Rs m | 142,531 | 18,091 | 787.9% | |
| Other income | Rs m | 1,139 | 127 | 899.1% | |
| Total revenues | Rs m | 143,670 | 18,217 | 788.6% | |
| Gross profit | Rs m | 24,198 | -3,135 | -771.9% | |
| Depreciation | Rs m | 6,965 | 781 | 892.0% | |
| Interest | Rs m | 3,418 | 490 | 697.5% | |
| Profit before tax | Rs m | 14,954 | -4,279 | -349.5% | |
| Minority Interest | Rs m | 288 | -12 | -2,414.5% | |
| Prior Period Items | Rs m | 0 | 0 | - | |
| Extraordinary Inc (Exp) | Rs m | 0 | 0 | - | |
| Tax | Rs m | 3,198 | 267 | 1,196.0% | |
| Profit after tax | Rs m | 12,044 | -4,558 | -264.2% | |
| Gross profit margin | % | 17.0 | -17.3 | -98.0% | |
| Effective tax rate | % | 21.4 | -6.2 | -342.2% | |
| Net profit margin | % | 8.5 | -25.2 | -33.5% | |
| BALANCE SHEET DATA | |||||
|---|---|---|---|---|---|
| Current assets | Rs m | 87,154 | 13,250 | 657.8% | |
| Current liabilities | Rs m | 82,694 | 7,455 | 1,109.2% | |
| Net working cap to sales | % | 3.1 | 32.0 | 9.8% | |
| Current ratio | x | 1.1 | 1.8 | 59.3% | |
| Inventory Days | Days | 71 | 111 | 64.4% | |
| Debtors Days | Days | 94 | 124 | 75.7% | |
| Net fixed assets | Rs m | 133,236 | 7,723 | 1,725.1% | |
| Share capital | Rs m | 1,024 | 84 | 1,219.1% | |
| Net worth | Rs m | 103,757 | 14,199 | 730.7% | |
| Long term debt | Rs m | 32,146 | 4,990 | 644.2% | |
| Total assets | Rs m | 236,866 | 26,824 | 883.1% | |
| Interest coverage | x | 5.4 | -7.7 | -69.5% | |
| Debt to equity ratio | x | 0.3 | 0.4 | 88.2% | |
| Sales to assets ratio | x | 0.6 | 0.7 | 89.2% | |
| Return on assets | % | 6.5 | -15.2 | -43.0% | |
| Return on equity | % | 11.6 | -32.1 | -36.2% | |
| Return on capital | % | 13.7 | -19.8 | -69.3% | |
| CASH FLOW | |||||
|---|---|---|---|---|---|
| From Operations | Rs m | 25,054 | 1,544 | 1,622.5% | |
| From Investments | Rs m | -10,123 | -474 | 2,135.0% | |
| From Financial Activity | Rs m | -10,942 | 4,529 | -241.6% | |
| Net Cashflow | Rs m | 3,989 | 5,599 | 71.2% | |
The reporting currency for ADCOCK INGRAM (S. Africa) is South Africa Rand. All data has been converted at 4.97 Rs / ZAR
Compare CADILA HEALTHCARE With: ACTAVIS (US) MYLAN (US) TEVA PHARMA (Israel)
Compare CADILA HEALTHCARE With: JUBILANT LIFE SCIENCES PROCTER & GAMBLE HEALTH AUROBINDO PHARMA SANOFI INDIA NOVARTIS
Today's Market
Sensex Zooms 1,030 Points, Nifty Tops 14,980-Mark; HDFC Bank Among Top Gainers(Closing)
Indian share markets witnessed huge buying interest during the extended closing hours today and ended their day on a strong note.
Related Views On News
CADILA HEALTHCARE Announces Quarterly Results (3QFY21); Net Profit Up 40.6% (Quarterly Result Update)
Feb 10, 2021 | Updated on Feb 10, 2021For the quarter ended December 2020, CADILA HEALTHCARE has posted a net profit of Rs 5 bn (up 40.6% YoY). Sales on the other hand came in at Rs 38 bn (up 4.3% YoY). Read on for a complete analysis of CADILA HEALTHCARE's quarterly results.
CADILA HEALTHCARE 2019-20 Annual Report Analysis (Annual Result Update)
Oct 26, 2020 | Updated on Oct 26, 2020Here's an analysis of the annual report of CADILA HEALTHCARE for 2019-20. It includes a full income statement, balance sheet and cash flow analysis of CADILA HEALTHCARE. Also includes updates on the valuation of CADILA HEALTHCARE.
CADILA HEALTHCARE Announces Quarterly Results (1QFY21); Net Profit Up 49.3% (Quarterly Result Update)
Aug 21, 2020 | Updated on Aug 21, 2020For the quarter ended June 2020, CADILA HEALTHCARE has posted a net profit of Rs 5 bn (up 49.3% YoY). Sales on the other hand came in at Rs 36 bn (up 4.1% YoY). Read on for a complete analysis of CADILA HEALTHCARE's quarterly results.
More Views on NewsMost Popular
Intraday Trading for a Living (Fast Profits Daily)
Feb 15, 2021In this video, I'll cover your queries on intraday trading and also share my view on how to decide stop losses and target prices.
Penny Stock Master Series: The Quest for 10X Profits in 10 Years (Profit Hunter)
Feb 12, 2021This is first of the three part master series. In these editorials, I'll show you how to earn 10X returns from a penny stock portfolio over 10 years.
Top 5 Stocks Mutual Funds Bought and Sold in January 2021 (Sector Info)
Feb 16, 2021A look at what India's top equity mutual funds bought and sold in January 2021.
I Would Recommend this Small-cap Stock Over Tesla (Profit Hunter)
Feb 16, 2021Do you enjoy reading Tesla and Bitcoin stories? Here's a not so famous small-cap stock to profit from the rise of EVs.
More
